17 apr: FOCUS: Food Processors To Benefit From Cheaper Grain Prices
17 apr: UPDATE: Marathon Oil: Angola's Block 31 To Start Product..
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
27 aug - 
Onsdagens aktier: Hæderlig aktiedag trods småsurt Europ..
27 aug - 
Onsdagens aktier: Hæderlig aktiedag trods småsurt Europ..
27 aug - 
Aktier/middag: Stille, men positiv dag
Relateret debat
27 aug - 
http://borsen.dk/nyheder/virksomheder/artikel/1/289488/..
26 aug - 
Hej Taastrup, Køber du lige op til eller afventer du på..
26 aug - 
Vent nu til 19 September og se hvad som sker i usa... J..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
26 aug
NOVO-B
Drop dog jeres smarte kommentarer og brug tråden til noget konstruktivt! Jeg fik solgt idag i høje..
2
26 aug
NOVO-B
Goodie hvorfor falder vws idag , var der ikke en der sagde den skulle i 400 i august, LOL
2
26 aug
NOVO-B
Tror sgu bare han bare er en sølle kontantshjælpsmodtager der lever i sin egen verden  
1
26 aug
NOVO-B
Ja og så skrev han i weekenden, at Vestas ville stige helt vildt igår. Det var vel også for sjovt
1
26 aug
NOVO-B
Haha havde ikke lige læst Tyros indlæg
1
26 aug
NOVO-B
Det morer mig så meget at du er så blank at du virkelig tror at jeg mener noget som helst om mine sp..
1
26 aug
NOVO-B
Kan huske en, som for nogen tid siden flere gange skrev, at kursen på vestas vil være 400 til august..
1
26 aug
NOVO-B
Sig mig en gang, hvorfor stiger Novo dog ?   Var der ikke nogle kloge herinde som SAGTENS kunne se d..
1

Euroinvestor.com A/S løfter omsætningen og indtjeningen markant.

29-08-2014 10:55:42
Delårsrapport 2014 for Euroinvestor.com A/S Fondsbørsmeddelelse nr. 11. 2014  29. august 2014 Resumé: Delårsrapport 2014 ..

Aktier/tendens: Regnskaber, nøgletal og Rusland/Ukraine i fokus

29-08-2014 08:30:15
Det tegner til en flad til let positiv udvikling for de danske aktier, når markedet åbner fredag kl. 9:00. Futures på de store europæiske børser peger i hvert f..

Vestas: Energiagentur advarer om afmatning

28-08-2014 16:00:21
Usikkerhed om politiske rammebetingelser truer med at dæmpe momentum for investering i vedvarende energiprojekter, konkluderer det internationale energiagentur,..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Regnskaber, nøgletal og Rusland/Ukraine i fokus
2
Vestas får finsk ordre på 30 MW - NY
3
Brøndby dribler langsomt fra sit underskud
4
Aktier/middag: OW Bunker straffes hårdt i fladt marked
5
Brøndby IF sælger Simon Makienok til italiensk klub - NY

Relaterede aktiekurser

Novo Nordisk B A/S 259,00 0,4% Stigning i aktiekurs
Novo-Nordisk A/S 45,96 0,6% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
30. august 2014 08:11:35
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140825.1 - EUROWEB7 - 2014-08-30 08:11:35 - 2014-08-30 08:11:35 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x